## Mayo Clinic Minute:

## Esketamine

Video	Audio		
FDA website scroll on approval	Esketamine, a version of the drug ketamine, has been approved for treatment-resistant depression.		
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm632761.htm			
Jennifer Vande Voort, M.D. Psychiatry Mayo Clinic	"Ketamine is a mixture of two enantiomers of a drug, meaning that it has two molecules in it. So esketamine is one molecule of the drug ketamine."		
1:14			
Clip 5			
Pharmacy shots -	Dr. Jennifer Vande Voort says these drugs are unlike other antidepressants.		
2:10	"They provide a rapid-acting antidepressant response,		
Clip 5	and they also have anti-suicidal properties."		
https://www.spravatohcp.com/dosing-and-administration	So how does esketamine work?		
3:40 Clip 5	"When we have depression, sometimes we don't have as many connections or synapses within the brain cells, so those synapses go away. Esketamine is thought to create these synapses, or connections, between our brain cells again."		
http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf	Esketamine is prescribed as a nasal spray that must be administered in a clinical setting. And it's not for everyone.		
SOT 8:00 Clip 5	"They have to fail two antidepressant trials at adequate dosages and durations."		
People in shadow - depression broll	Dr. Vande Voort says for the right people, there is great promise with esketamine.		
Clip 5 6:45	breat promise with esketamine.		
	For the Mayo Clinic News Network, I'm Ian Roth.		